ArticleLeukemia & lymphoma2018

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.

Joseph Roswarski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.